Quick View: Stelara Biosimilar Competition In Europe Intensifies Following Pyzchiva Approval
Healthcare / Europe / Thu 25 Apr, 2024
The Latest: On April 22, 2024, the European Commission (EC) granted approval to Samsung Bioepis’s Pyzchiva (ustekinumab), a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), thereby broadening the range of treatment options for patients with chronic inflammatory conditions. Pyzchiva is indicated for the treatment of plaque psoriasis